Response to Gilks et al

To the Editor: The crux of this letter is a disagreement with the term ‘high-grade endometrioid carcinoma’. First, the authors point out that the diagnosis is not easily reproduced between pathologists. Second, they state that the molecular data indicate very little difference between high-grade endometrioid and high-grade serous carcinomas.1 Third, they perceive that continued use of the term ‘high-grade endometrioid’ will create confusion that will be detrimental to patient care. Fourth, they imply that the differences in the frequencies of two parameters—tubal intraepithelial carcinoma and dominant ovarian mass—in cases of high-grade serous and endometrioid carcinomas are insufficient reason to separate them.